TY - JOUR
T1 - Two Synthetic Antibodies that Recognize and Neutralize Distinct Proteolytic Forms of the Ebola Virus Envelope Glycoprotein
AU - Koellhoffer, Jayne F.
AU - Chen, Gang
AU - Sandesara, Rohini G.
AU - Bale, Shridhar
AU - Ollmann Saphire, Erica
AU - Chandran, Kartik
AU - Sidhu, Sachdev S.
AU - Lai, Jonathan R.
PY - 2012/11
Y1 - 2012/11
N2 - Ebola virus (EBOV) is a highly pathogenic member of the Filoviridae family of viruses that causes severe hemorrhagic fever. Infection proceeds through fusion of the host cell and viral membranes, a process that is mediated by the viral envelope glycoprotein (GP). Following endosomal uptake, a key step in viral entry is the proteolytic cleavage of GP by host endosomal cysteine proteases. Cleavage exposes a binding site for the host cell receptor Niemann-Pick C1 (NPC1) and may induce conformational changes in GP leading to membrane fusion. However, the precise details of the structural changes in GP associated with proteolysis and the role of these changes in viral entry have not been established. Here, we have employed synthetic antibody technology to identify antibodies targeting EBOV GP prior to and following proteolysis (i.e. in the "uncleaved" [GPUNCL] and "cleaved" [GPCL] forms). We identified antibodies with distinct recognition profiles: FabCL bound preferentially to GPCL (EC50=1.7 nM), whereas FabUNCL bound specifically to GPUNCL (EC50=75 nM). Neutralization assays with GP-containing pseudotyped viruses indicated that these antibodies inhibited GPCL- or GPUNCL-mediated viral entry with specificity matching their recognition profiles (IC50: 87 nM for IgGCL; 1 μM for FabUNCL). Competition ELISAs indicate that FabCL binds an epitope distinct from that of KZ52, a well-characterized EBOV GP antibody, and from that of the luminal domain of NPC1. The binding epitope of FabUNCL was also distinct from that of KZ52, suggesting that FabUNCL binds a novel neutralization epitope on GPUNCL. Furthermore, the neutralizing ability of FabCL suggests that there are targets on GPCL available for neutralization. This work showcases the applicability of synthetic antibody technology to the study of viral membrane fusion, and provides new tools for dissecting intermediates of EBOV entry.
AB - Ebola virus (EBOV) is a highly pathogenic member of the Filoviridae family of viruses that causes severe hemorrhagic fever. Infection proceeds through fusion of the host cell and viral membranes, a process that is mediated by the viral envelope glycoprotein (GP). Following endosomal uptake, a key step in viral entry is the proteolytic cleavage of GP by host endosomal cysteine proteases. Cleavage exposes a binding site for the host cell receptor Niemann-Pick C1 (NPC1) and may induce conformational changes in GP leading to membrane fusion. However, the precise details of the structural changes in GP associated with proteolysis and the role of these changes in viral entry have not been established. Here, we have employed synthetic antibody technology to identify antibodies targeting EBOV GP prior to and following proteolysis (i.e. in the "uncleaved" [GPUNCL] and "cleaved" [GPCL] forms). We identified antibodies with distinct recognition profiles: FabCL bound preferentially to GPCL (EC50=1.7 nM), whereas FabUNCL bound specifically to GPUNCL (EC50=75 nM). Neutralization assays with GP-containing pseudotyped viruses indicated that these antibodies inhibited GPCL- or GPUNCL-mediated viral entry with specificity matching their recognition profiles (IC50: 87 nM for IgGCL; 1 μM for FabUNCL). Competition ELISAs indicate that FabCL binds an epitope distinct from that of KZ52, a well-characterized EBOV GP antibody, and from that of the luminal domain of NPC1. The binding epitope of FabUNCL was also distinct from that of KZ52, suggesting that FabUNCL binds a novel neutralization epitope on GPUNCL. Furthermore, the neutralizing ability of FabCL suggests that there are targets on GPCL available for neutralization. This work showcases the applicability of synthetic antibody technology to the study of viral membrane fusion, and provides new tools for dissecting intermediates of EBOV entry.
KW - Antibody engineering
KW - Ebola virus
KW - Filovirus
KW - Phage display
KW - Synthetic antibodies
KW - Viral membrane fusion
UR - http://www.scopus.com/inward/record.url?scp=84869465815&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84869465815&partnerID=8YFLogxK
U2 - 10.1002/cbic.201200493
DO - 10.1002/cbic.201200493
M3 - Article
C2 - 23111988
AN - SCOPUS:84869465815
SN - 1439-4227
VL - 13
SP - 2549
EP - 2557
JO - ChemBioChem
JF - ChemBioChem
IS - 17
ER -